ORIGINAL ARTICLE
Sex differences in cardiovascular outcome during progression of aortic valve stenosis

Dana Cramariuc,1 Barbara Patricia Rogge,1,2 Mai Tone Lønnebakken,2 Kurt Boman,3 Edda Bahlmann,4 Christa Gohlke-Bärwolf,5 John B Chambers,6 Terje R Pedersen,7 Eva Gerds2

ABSTRACT
Objective Women with severe aortic valve stenosis (AS) have better LV systolic function and more concentric LV geometry than their male counterparts. However, sex differences in cardiovascular (CV) outcome during progression of AS have not been reported from a longitudinal prospective study.

Methods Doppler echocardiography and CV events were recorded during a median of 4.0 years in 979 men and 632 women aged 28–86 (mean 67±10) years in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study. LV systolic function was assessed by EF and midwall shortening (MWS). Study outcomes were AS-related events, ischaemic CV events and total mortality.

Results The annual cumulative incidence of AS events, ischaemic CV events and death was 8.1%, 3.4% and 2.8% in women, and 8.9%, 4.4% and 2.4% in men, respectively. Women and men had similar AS progression rate whether measured by peak jet velocity, mean gradient or valve area. In multivariate analyses, female sex independently predicted less reduction in LV MWS and EF during follow-up (both p<0.05). In time-varying Cox analyses, women had a 40% lower rate of AS event whether measured by peak jet velocity, mean gradient or valve area. In multivariate analyses, female sex independently predicted less reduction in LV MWS and EF during follow-up (both p<0.05). In time-varying Cox analyses, women had a 40% lower rate of AS event rate did not differ by sex.

Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders.

Trial registration number ClinicalTrials.gov identifier: NCT00092677.

Aortic valve stenosis (AS) is present in 2%–7% of the population above 65 years of age and is the most common type of valvular heart disease requiring open heart surgery in developed countries.1,2 Management of AS is based upon assessment of clinical cardinal symptoms and of AS severity.3 Echocardiography is the key technique to assess AS severity and structural and functional consequences for the LV.4

Previous cross-sectional studies in patients with severe, symptomatic AS have found that women present better LV systolic function than men, and more concentric LV geometry.5–8 Recently, women were found to have lower aortic valve calcium score by Agatston units on multislice CT than men for the same severity of AS.9 Furthermore, sex differences in comorbidities like hypertension, renal dysfunction and coronary artery disease are well known in patients with AS.10–12 However, although sex differences in comorbidities as well as in the pathophysiology of AS both at the aortic valve and LV level have been described, it is not clear whether women and men with AS have different progression rates or prognosis.13

The present, prospectively planned analysis aimed to compare AS progression rate and cardiovascular (CV) outcome between women and men during progression of AS.

METHODS

Study population

The Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study was a randomised, double-blind, placebo-controlled study which assessed the effect of combined treatment with simvastatin and ezetimibe on AS progression and CV morbidity and mortality in 1873 patients with initially asymptomatic, mild-moderate AS.14 Patients with known coronary artery disease, peripheral arterial disease, cerebrovascular disease, diabetes mellitus or any condition requiring lipid-lowering therapy were excluded from the SEAS study. The present prospectively planned analysis included the 1611 patients in whom LV geometry could be assessed on the echocardiogram both at baseline and at least one additional visit before occurrence of any major study outcome.

Hypertension was defined as history of hypertension, use of antihypertensive treatment reported by the attending physician or blood pressure ≥140/90 mm Hg at the baseline clinical visit.12 Blood tests, including measures of serum total and low-density lipoprotein (LDL)-cholesterol and assessment of kidney function by serum creatinine, were analysed at the SEAS core laboratory, PPD Global Central Labs (Zaventum, Belgium).

Echocardiographic measurements

Echocardiography was performed at baseline and then annually and before valve surgery at the 173 SEAS participating centres following a standardised performance protocol.10 12 The last study visit was...
defined as the last echocardiogram performed before a CV event in patients who experienced study endpoints or as the final study echocardiogram in those without events. All echocardiographic analyses were performed at the SEAS Echocardiography Core Laboratory at Haukeland University Hospital, Bergen, Norway, following current guidelines. Assessments of LV geometry

LV mass was calculated by the Devereux equation, and LV hypertrophy was considered present if LV mass/height^2.7 ≥46.7 g/m^2.7 in women and 49.2 g/m^2.7 in men. Concentric geometry was considered present if relative wall thickness ≥0.43. Abnormal LV geometry was considered present if either LV hypertrophy or increased relative wall thickness was found.

Assessment of LV systolic function

LVEF was measured by the Simpson’s biplane method. Gender-specific cut-off values for identification of low LV systolic function were used for EF and midwall shortening (MWS). EF was considered low if <51% in men and <55% in women. MWS was calculated using validated equations and considered low if <14% in men and <16% in women.

Study outcomes

The primary endpoint in the SEAS study was major CV events (combined AS-related events and ischaemic CV events). AS-related events included combined aortic valve replacement, hospitalisation for congestive heart failure due to AS or death from CV causes. Ischaemic CV events included combined non-fatal myocardial infarction, hospitalisation for unstable angina, coronary revascularisation at the time of aortic valve replacement, non-hemorrhagic stroke and CV death. The present analysis also assessed all-cause mortality, a tertiary study endpoint. All study endpoints were adjudicated by an independent classification committee.

Statistical analyses

Comparisons between women and men were done by χ^2 test, unpaired Student’s t test, full-factorial two-way analysis of variance (ANOVA) with Sidak’s posthoc test or ANOVA for repeated measures, as appropriate. Independent covariates of reduction in EF and MWS from baseline to the last study visit were identified in multivariate linear regression analyses, run with an enter procedure and collinearity diagnostics. The impact of sex on rate of AS-related and ischaemic CV events and on total mortality was tested in univariate and multivariate time-varying Cox proportional hazard analyses including age, hypertension and active study treatment, as well as AS severity by ELI, presence of low EF and low MWS, and abnormal LV geometry as time-varying covariates. Results are presented as HRs with 95% CI, as well as plots of survival free of ischaemic CV events and overall survival in women and men with adjustment for the mean values of the other covariates included in the multivariate Cox models. Two-tailed p≤0.05 was considered significant both in univariate and multivariate analyses.

RESULTS

Progression of AS

Women were older (69±9 vs. 66±10 years), included more patients with hypertension (91% vs. 83%) and had better renal function than men (all p<0.001, table 1). Sixteen per cent of

<table>
<thead>
<tr>
<th>Table 1 Clinical and echocardiographical characteristics of women and men at baseline and at the last study visit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Women (632)</strong></td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Body mass index (kg/m^2)</strong></td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mm Hg)</strong></td>
</tr>
<tr>
<td><strong>Diastolic blood pressure (mm Hg)</strong></td>
</tr>
<tr>
<td><strong>Heart rate (beats/min)</strong></td>
</tr>
<tr>
<td><strong>Total cholesterol (mmol/L)</strong></td>
</tr>
<tr>
<td><strong>LDL cholesterol (mmol/L)</strong></td>
</tr>
<tr>
<td><strong>Creatinine (µmol/L)</strong></td>
</tr>
<tr>
<td><strong>Serum glucose (mmol/L)</strong></td>
</tr>
<tr>
<td><strong>Peak aortic jet velocity (m/s)</strong></td>
</tr>
<tr>
<td><strong>Mean transvalvular gradient (mm Hg)</strong></td>
</tr>
<tr>
<td><strong>Aortic valve area (cm^2)</strong></td>
</tr>
<tr>
<td><strong>Aortic valve area index (cm^2/m^2)</strong></td>
</tr>
<tr>
<td><strong>ELI (cm^2/m^2)</strong></td>
</tr>
<tr>
<td><strong>EF (%)</strong></td>
</tr>
<tr>
<td><strong>MWS (%)</strong></td>
</tr>
<tr>
<td><strong>LV mass index (g/m^3.5)</strong></td>
</tr>
<tr>
<td><strong>Relative wall thickness</strong></td>
</tr>
<tr>
<td><strong>Mitral regurgitation (mild/moderate)</strong></td>
</tr>
<tr>
<td><strong>Aortic regurgitation (mild/moderate)</strong></td>
</tr>
</tbody>
</table>

Data are means±SD.
* p<0.001 and † p<0.05 between women and men at either baseline or last visit; ‡ p<0.01 in women for comparison between values at baseline and at last visit; § p<0.01 in men for comparison between values at baseline and at last visit.

ELI, energy loss index; MWS, midwall shortening; LDL, low-density lipoprotein.
women were smokers at study baseline vs. 21% of men (p<0.05).
Women also had smaller aortic valve area both at inclusion and at
the last study visit, also when adjusted for pressure recovery in the
aortic root, indicating more severe AS (table 1 and figure 1).
Mild–moderate mitral regurgitation was more prevalent in
women and mild–moderate aortic regurgitation more prevalent
in men (both p<0.05) (table 1). No patient had severe mitral or
aortic valve regurgitation, reflecting the exclusion criteria in the
SEAS study.
Although there was no stratification by sex in the randomisation
procedure, randomisation to active study treatment did not
differ between sexes: 50% of women on active treatment vs.
51% of men (p=0.61).
During a median of 4 years follow-up, AS progression rate
did not differ between women and men, whether assessed from
peak aortic jet velocity, mean transvalvular gradient, aortic valve
area, aortic valve area index or ELI (table 2).
Low EF was uncommon in this population, reflecting the
exclusion criteria used in the SEAS study. New-onset low EF was
equally common in women and men during follow-up (figure 2).
However, the absolute reduction in EF from baseline to the last
examination was significantly larger in men (2.6% vs. 1.4%,
p<0.01) (table 1). Despite the low prevalence of reduced EF, low
MWS was commonly found (p<0.001 at all visits, figure 2).
In multivariate regression analyses, male sex independently
predicted larger reduction both in EF and MWS during progression of AS (table 3). Baseline kidney function assessed by the
serum creatinine level did not significantly influence reduction in
EF or MWS in similar regression models.

**CV outcome**

During follow-up (median 4.0 years, IQR 3.0–4.2 years), a total of
554 major CV events occurred, among them 517 AS-related
events and 260 ischaemic CV events. The ischaemic events
included 56 strokes, 142 deaths from any cause (71 from CV
causes), 28 non-fatal myocardial infarctions, 11 hospitalisations
for unstable angina, 20 percutaneous coronary interventions
and 142 coronary artery bypass revascularisations. Women had
significantly lower risk of major CV events and ischaemic CV
events (figure 3), also after adjustment for active study treat-
ment, age and hypertension and time-varying ELI, low EF, low
MWS and abnormal LV geometry in time-varying multivariate
Cox analyses (table 4). Neither higher total cholesterol at base-
line nor LDL cholesterol was associated with higher rate of

---

**Table 2** Annual progression rate of aortic stenosis in women and men

<table>
<thead>
<tr>
<th></th>
<th>Women (632)</th>
<th>Men (979)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak aortic jet velocity (m/s/year)</td>
<td>0.21±0.26</td>
<td>0.19±0.31</td>
<td>0.13</td>
</tr>
<tr>
<td>Mean transvalvular gradient (mm Hg/year)</td>
<td>4±5</td>
<td>4±6</td>
<td>0.15</td>
</tr>
<tr>
<td>Aortic valve area (cm²/year)</td>
<td>0.04±0.14</td>
<td>0.03±0.32</td>
<td>0.77</td>
</tr>
<tr>
<td>Aortic valve area index (cm²/m²/year)</td>
<td>0.02±0.08</td>
<td>0.02±0.16</td>
<td>0.63</td>
</tr>
<tr>
<td>ELI (cm²/m²/year)</td>
<td>0.06±0.13</td>
<td>0.05±0.23</td>
<td>0.52</td>
</tr>
</tbody>
</table>

ELI, energy loss index.
ischaemic CV events when added to the time-varying Cox model run in the whole study population as well as separately in women and men. When current smoking at baseline was added to these models, the results remained unchanged. Analysing the association between sex and specific types of ischaemic CV events using similar Cox models, female sex predicted more than 50% lower rate of both stroke and coronary artery disease requiring concomitant bypass grafting at the time of aortic valve replacement (table 4). Women also had a 31% lower all-cause mortality rate independent of covariates (table 4 and figure 4).

The annular incidence of ischaemic CV events was 3.4% in women and 4.4% in men (p<0.007).

DISCUSSION

The present large, prospective, longitudinal study is the first to report on AS progression and associated CV events using a sex-specific approach. In particular, women and men had similar AS progression rates. However, women had lower total mortality despite more severe AS by echocardiographic indices and also lower rate of ischaemic CV events during a median of 4 years follow-up. The present study extends previous knowledge on sex differences from cross-sectional studies in AS which have demonstrated pathophysiological differences between women and men both at the aortic valve and LV level, including less valve calcification, more concentric LV geometry and extracellular myocardial fibrosis and higher indices of LV systolic function in women.5–7 9 18–20

Progression of AS in women and men

Few studies have compared AS progression in women and men. The Cardiovascular Health Study including echocardiographic follow-up over a mean of 5 years in 5621 subjects ≥65 years of age reported that 9% of subjects with aortic valve sclerosis at the initial examination had progressed to AS on the follow-up.

The prevalence of low midwall shortening and low EF in women and men is shown in figure 2. The prevalence of low EF increased over time in both women and men, whereas the prevalence of low midwall shortening remained stable in women but increased in men. The difference between women and men remained significant in all study visits. The prevalence of low EF in women at year 2 was higher than in men (p<0.001). The prevalence of low midwall shortening in women and men at baseline and year 2 was similar (p=0.13).

The Kaplan–Meier estimates of survival free of ischaemic CV events in women and men during progression of aortic valve stenosis with adjustment for covariates (the means of age, hypertension, active study treatment, energy loss index, low EF and midwall shortening, and abnormal LV geometry) and p value of significance based on Cox proportional hazard analyses is shown in figure 3. The Kaplan–Meier method provides a graphical representation of the probability of an event occurring over time, allowing for comparison of survival rates between different groups.

Table 3 shows the predictors of reduction in LVEF and MWS from baseline to the last study visit. Male sex, age, active study treatment, reduction in ELI, presence of aortic regurgitation, presence of mitral regurgitation, LV hypertrophy, and baseline MWS were significant predictors of reduction in LVEF, whereas male sex, age, active study treatment, reduction in ELI, and LV hypertrophy were significant predictors of reduction in MWS. The table also presents the p values for each predictor, with values <0.05 indicating statistical significance.

Table 4 shows the association of female sex with rates of major CV events, ischaemic CV events and death in time-varying multivariate Cox analyses adjusting for active study treatment, age and hypertension, as well as time-varying ELI, low EF, low MWS and abnormal LV geometry. Female sex was associated with a lower risk of major CV events (HR 0.83, 95% CI 0.69 to 0.99), ischaemic events (HR 0.60, 95% CI 0.46 to 0.79), stroke (HR 0.47, 95% CI 0.26 to 0.85), coronary artery bypass grafting (HR 0.49, 95% CI 0.34 to 0.71), non-fatal myocardial infarction (HR 1.15, 95% CI 0.52 to 2.54), hospitalisation for unstable angina (HR 0.62, 95% CI 0.17 to 2.20), percutaneous coronary intervention (HR 0.62, 95% CI 0.21 to 1.82), and death (HR 0.69, 95% CI 0.49 to 0.99). The associations were significant for ischaemic events, stroke, and hospitalisation for unstable angina (p<0.001 for all).

**Table 3** Predictors of reduction in LVEF (multiple R²=0.39, p<0.001) and MWS (multiple R²=0.51, p<0.001) from baseline to the last study visit

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Reduction in EF</th>
<th>Reduction in MWS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>p Value</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.02</td>
<td>0.42</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>0.08</td>
<td>0.001</td>
</tr>
<tr>
<td>Active study treatment</td>
<td>0.03</td>
<td>0.25</td>
</tr>
<tr>
<td>Reduction in ELI (cm²/m²)</td>
<td>−0.03</td>
<td>0.24</td>
</tr>
<tr>
<td>Presence of aortic regurgitation</td>
<td>0.01 in male, −0.01 in female</td>
<td>0.68 in male, −0.01 in female</td>
</tr>
<tr>
<td>Presence of mitral regurgitation</td>
<td>0.05 in male, 0.02 in female</td>
<td>0.02 in male, 0.01 in female</td>
</tr>
<tr>
<td>LV hypertrophy</td>
<td>0.12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Concentric LV geometry</td>
<td>−0.04</td>
<td>0.11</td>
</tr>
<tr>
<td>Baseline EF (%)</td>
<td>0.60</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline MWS (%)</td>
<td>−0.03</td>
<td>0.37</td>
</tr>
</tbody>
</table>

ELI, energy loss index; MWS, midwall shortening.

**Table 4** The association of female sex with rates of major CV events, ischaemic CV events and death in time-varying multivariate Cox analyses adjusting for active study treatment, age and hypertension, as well as time-varying ELI, low EF, low MWS and abnormal LV geometry

<table>
<thead>
<tr>
<th>Event</th>
<th>HR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major CV events</td>
<td>0.83 (0.69 to 0.99)</td>
<td>0.04</td>
</tr>
<tr>
<td>Aortic valve events</td>
<td>0.85 (0.70 to 1.02)</td>
<td>0.08</td>
</tr>
<tr>
<td>Ischaemic events</td>
<td>0.60 (0.46 to 0.79)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>stroke</td>
<td>0.47 (0.26 to 0.85)</td>
<td>0.01</td>
</tr>
<tr>
<td>coronary artery bypass grafting</td>
<td>0.49 (0.34 to 0.71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>non-fatal myocardial infarction</td>
<td>1.15 (0.52 to 2.54)</td>
<td>0.724</td>
</tr>
<tr>
<td>hospitalisation for unstable angina</td>
<td>0.62 (0.17 to 2.20)</td>
<td>0.456</td>
</tr>
<tr>
<td>percutaneous coronary intervention</td>
<td>0.62 (0.21 to 1.82)</td>
<td>0.386</td>
</tr>
<tr>
<td>Death</td>
<td>0.69 (0.49 to 0.99)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

CV, cardiovascular; ELI, energy loss index; MWS, midwall shortening.
Sex-related differences in atherosclerosis progression, plaque composition and prevalence of microvascular disease have been well documented. Obstructive coronary artery disease and stroke are both more prevalent among men in the general population <75 years of age. Recently, superior LV hypertrophy regression and outcome were reported in elderly women compared with men undergoing transcatheter aortic valve replacement from the prospective Placement of Aortic Transcatheter Valve (PARTNER) trial. This report is based on the prospective follow-up of a selected population of patients with AS and without diabetes mellitus, clinical manifest vascular disease, dyslipidaemia, or other significant valvular disease participating in the SEAS study. Exclusion of patients with diabetes mellitus was done based upon known history of diabetes. Inclusion of some patients with subclinical diabetes mellitus might have occurred, since HbA1c was not measured. Extrapolation of the results to other types of patients with AS should be done with caution. However, in patients with AS with clustering of CV risk factors or established CV disease, even higher incidence of ischaemic CV events is to be expected, and active CV prevention may be even more effective.

In conclusion, the present results demonstrate that women and men have similar rates of AS progression and AS-related events. However, women have lower total mortality and impaired prognosis in AS. Reduced LVEF to <50% is a guideline indication for valve replacement in severe AS. As demonstrated, men experienced more reduction in EF and more subclinical coronary artery disease during follow-up, but low EF was very uncommon, probably reflecting the SEAS study exclusion criteria. These preoperative differences may help explain the observed higher LVEF and enhanced hypertrophy regression in women in previous studies after aortic valve replacement for AS, as well as the recent findings of better survival in elderly women undergoing transcatheter aortic valve replacement in a retrospective sub-analysis from the PARTNER trial.

Study limitations
This report is based on the prospective follow-up of a selected population of patients with AS and without diabetes mellitus, clinical manifest vascular disease, dyslipidaemia, or other significant valvular disease participating in the SEAS study. Exclusion of patients with diabetes mellitus was done based upon known history of diabetes. Inclusion of some patients with subclinical diabetes mellitus might have occurred, since HbA1c was not measured. Extrapolation of the results to other types of patients with AS should be done with caution. However, in patients with AS with clustering of CV risk factors or established CV disease, even higher incidence of ischaemic CV events is to be expected, and active CV prevention may be even more effective.

In conclusion, the present results demonstrate that women and men have similar rates of AS progression and AS-related events. However, women have lower total mortality and impaired prognosis in AS. Reduced LVEF to <50% is a guideline indication for valve replacement in severe AS. As demonstrated, men experienced more reduction in EF and more subclinical coronary artery disease during follow-up, but low EF was very uncommon, probably reflecting the SEAS study exclusion criteria. These preoperative differences may help explain the observed higher LVEF and enhanced hypertrophy regression in women in previous studies after aortic valve replacement for AS, as well as the recent findings of better survival in elderly women undergoing transcatheter aortic valve replacement in a retrospective sub-analysis from the PARTNER trial.

Study limitations
This report is based on the prospective follow-up of a selected population of patients with AS and without diabetes mellitus, clinical manifest vascular disease, dyslipidaemia, or other significant valvular disease participating in the SEAS study. Exclusion of patients with diabetes mellitus was done based upon known history of diabetes. Inclusion of some patients with subclinical diabetes mellitus might have occurred, since HbA1c was not measured. Extrapolation of the results to other types of patients with AS should be done with caution. However, in patients with AS with clustering of CV risk factors or established CV disease, even higher incidence of ischaemic CV events is to be expected, and active CV prevention may be even more effective.

In conclusion, the present results demonstrate that women and men have similar rates of AS progression and AS-related events. However, women have lower total mortality and impaired prognosis in AS. Reduced LVEF to <50% is a guideline indication for valve replacement in severe AS. As demonstrated, men experienced more reduction in EF and more subclinical coronary artery disease during follow-up, but low EF was very uncommon, probably reflecting the SEAS study exclusion criteria. These preoperative differences may help explain the observed higher LVEF and enhanced hypertrophy regression in women in previous studies after aortic valve replacement for AS, as well as the recent findings of better survival in elderly women undergoing transcatheter aortic valve replacement in a retrospective sub-analysis from the PARTNER trial.

Study limitations
This report is based on the prospective follow-up of a selected population of patients with AS and without diabetes mellitus, clinical manifest vascular disease, dyslipidaemia, or other significant valvular disease participating in the SEAS study. Exclusion of patients with diabetes mellitus was done based upon known history of diabetes. Inclusion of some patients with subclinical diabetes mellitus might have occurred, since HbA1c was not measured. Extrapolation of the results to other types of patients with AS should be done with caution. However, in patients with AS with clustering of CV risk factors or established CV disease, even higher incidence of ischaemic CV events is to be expected, and active CV prevention may be even more effective.

In conclusion, the present results demonstrate that women and men have similar rates of AS progression and AS-related events. However, women have lower total mortality and impaired prognosis in AS. Reduced LVEF to <50% is a guideline indication for valve replacement in severe AS. As demonstrated, men experienced more reduction in EF and more subclinical coronary artery disease during follow-up, but low EF was very uncommon, probably reflecting the SEAS study exclusion criteria. These preoperative differences may help explain the observed higher LVEF and enhanced hypertrophy regression in women in previous studies after aortic valve replacement for AS, as well as the recent findings of better survival in elderly women undergoing transcatheter aortic valve replacement in a retrospective sub-analysis from the PARTNER trial. As demonstrated, men experienced more reduction in EF and more subclinical coronary artery disease during follow-up, but low EF was very uncommon, probably reflecting the SEAS study exclusion criteria. These preoperative differences may help explain the observed higher LVEF and enhanced hypertrophy regression in women in previous studies after aortic valve replacement for AS, as well as the recent findings of better survival in elderly women undergoing transcatheter aortic valve replacement in a retrospective sub-analysis from the PARTNER trial.
Valvular heart disease

Ischaemic CV event rates compared with men during progression of AS, even after adjustment for confounding factors like differences in age, prevalence of hypertension, AS severity, LV geometry and LV systolic function.

Contributors DC, BPR, MTL and EG were involved in the conception and design, as well as analysis and interpretation of data. All coauthors have revised the manuscript critically and approved it for submission to Heart.

Funding The SEAS (Simvastatin Ezetimibe in Aortic Stenosis) Echocardiography Core Laboratory was supported by MSP Singapore Company, LLC, Singapore, a partnership between Merck Co, and the Schering-Plough Corporation.

Competing interests EG received steering committee honorarium and funding for the echocardiography core laboratory from Merck Schering Plough. TRP has received consulting fees and speaker honoraria from Merck Sharp and Dohme. KB received steering committee honorarium and speaker honoraria from Merck Schering Plough. The other authors have no disclosures related to the present study.

Patient consent Obtained.

Ethics approval The study was approved by all regional ethics committees.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
24 Pibarot P, Dumesnil JG. Assessment of aortic stenosis severity: check the valve but don’t forget the arteries! Heart 2007;93:780–2.
Sex differences in cardiovascular outcome during progression of aortic valve stenosis

Dana Cramariuc, Barbara Patricia Rogge, Mai Tone Lønnebakken, Kurt Boman, Edda Bahlmann, Christa Gohlke-Bärwolf, John B Chambers, Terje R Pedersen and Eva Gerdt

Heart 2015 101: 209-214 originally published online October 9, 2014
doi: 10.1136/heartjnl-2014-306078

Updated information and services can be found at:
http://heart.bmj.com/content/101/3/209

These include:

References
This article cites 28 articles, 12 of which you can access for free at:
http://heart.bmj.com/content/101/3/209#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Open access (236)
- Aortic valve disease (415)
- Drugs: cardiovascular system (8842)
- Epidemiology (3752)
- Hypertension (3006)
- Clinical diagnostic tests (4779)
- Interventional cardiology (2933)
- Echocardiography (2127)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/